TRVI - Trevi Therapeutics, Inc.
IEX Last Trade
4.14
-0.050 -1.208%
Share volume: 25,051
Last Updated: Thu 26 Dec 2024 08:30:08 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$4.19
-0.05
-1.19%
Fundamental analysis
21%
Profitability
25%
Dept financing
4%
Liquidity
50%
Performance
15%
Performance
5 Days
-1.48%
1 Month
38.89%
3 Months
26.98%
6 Months
50.94%
1 Year
179.72%
2 Year
116.22%
Key data
Stock price
$4.14
DAY RANGE
$4.00 - $4.21
52 WEEK RANGE
$1.36 - $4.68
52 WEEK CHANGE
$187.77
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Jennifer L. Good
Region: US
Website: trevitherapeutics.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: trevitherapeutics.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Trevi Therapeutics is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Recent news